Pharmacokinetics of Tricyclic Antidepressants

Introduction to TCAs

Tricyclic antidepressants have a plasma half-life ranging from 12-36 hours and reach peak plasma concentrations within 0.5-4 hours after oral administration 1, 2

TCAs are rapidly absorbed from the gastrointestinal tract with good bioavailability 1
Peak plasma concentrations typically occur within 0.5-4 hours after oral administration 1
Absorption may be affected by food intake, which can increase both absorption and bioavailability 3
TCAs have high distribution volumes and rapidly distribute from plasma to the central nervous system 1
They achieve 10-40 times higher concentrations in brain tissue than in blood 1
TCAs exhibit high plasma protein binding (90-99%), which affects their free concentration 1

The elimination half-life of TCAs ranges from 12-36 hours, primarily through hepatic metabolism 1, 2
Specific half-lives vary by compound:

TCAs undergo extensive first-pass metabolism in the liver, resulting in 10-70% systemic bioavailability 1
Metabolism primarily occurs through the cytochrome P450 enzyme system, particularly CYP2D6 and CYP2C19 1
Genetic polymorphisms in these enzymes can significantly affect TCA metabolism:
Active metabolites contribute to both therapeutic and adverse effects (e.g., nortriptyline is an active metabolite of amitriptyline) 4

Steady-state plasma concentrations are typically reached after 5-7 days of consistent dosing 4
Therapeutic ranges have been established for several TCAs:

Due to their relatively long half-lives, most TCAs can be administered once daily, typically at bedtime to minimize daytime sedation 4
The long half-life provides a buffer against missed doses, maintaining therapeutic effect 1
When discontinuing TCAs, the long half-life allows for gradual elimination, though tapering is still recommended to minimize discontinuation symptoms 5
When switching between antidepressants, the long half-life of TCAs must be considered to avoid drug interactions 1
Failure to account for genetic polymorphisms in metabolism can lead to unexpected toxicity or treatment failure 1